U.S. Markets open in 41 mins.

GenVec, Inc. (GNVC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.92+0.02 (+0.29%)
At close: 4:00PM EDT
People also watch
CYCCHEBCRISCTICCYTR

GenVec, Inc.

910 Clopper Road
Suite 220N
Gaithersburg, MD 20878
United States
240-632-0740
http://www.genvec.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees15

Key Executives

NameTitlePayExercisedAge
Mr. Douglas J. Swirsky CPA, CFAChief Exec. Officer, Pres, Corp. Sec. and Director644.12kN/A48
Dr. Douglas E. Brough Ph.D.Chief Scientific Officer410.47kN/A62
Dr. Bryan T. Butman Ph.D.Sr. VP of Devel.377.12kN/A64
Mr. James Vincent LambertSr. Director of Accounting & Fin., Treasurer and Corp. ControllerN/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The company’s lead product candidate is CGF166, which is in Phase I/II clinical trial for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to generate vaccine candidates for the prevention of malaria; Laboratory of Malaria Immunology and Vaccinology to create and test various malaria vaccine candidates; and Merial to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland.

Corporate Governance

GenVec, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.